IBIO Key Statistics, Chart & Performance
The current stock price of IBIO is 2.1801 USD. In the past month the price increased by 20.54%. In the past year, price decreased by -25.91%.
IBIO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IBIO. When comparing the yearly performance of all stocks, IBIO turns out to be only a medium performer in the overall market: it outperformed 59.17% of all stocks.
IBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IBIO. Both the profitability and financial health of IBIO have multiple concerns.
IBIO Financial Highlights
Over the last trailing twelve months IBIO reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS increased by 73.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| Debt/Equity | 0.05 |
IBIO Forecast & Estimates
10 analysts have analysed IBIO and the average price target is 4.61 USD. This implies a price increase of 111.48% is expected in the next year compared to the current price of 2.1801.
For the next year, analysts expect an EPS growth of 81.54% and a revenue growth -25% for IBIO
IBIO Ownership
About IBIO
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Company Info
IBIO INC
11750 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 77807 US
CEO: Thomas F. Isett
Employees: 20
Phone: 19794460027
IBIO INC / IBIO FAQ
What does IBIO INC do?
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
What is the current price of IBIO stock?
The current stock price of IBIO is 2.1801 USD. The price decreased by -2.24% in the last trading session.
What is the dividend status of IBIO INC?
IBIO does not pay a dividend.
How is the ChartMill rating for IBIO INC?
IBIO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for IBIO INC?
IBIO INC (IBIO) operates in the Health Care sector and the Biotechnology industry.
Would investing in IBIO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IBIO.
What is the market capitalization of IBIO stock?
IBIO INC (IBIO) has a market capitalization of 49.03M USD. This makes IBIO a Nano Cap stock.